Boston University’s Mark Grinstaff has been awarded a new National Institute of Health/National Cancer Institute (NIH/NCI) R01 grant. The funding will be used in collaboration with University of North Carolina Greensboro (UNCG), Augusta University, Brigham and Women’s Hospital (BWH) and Mycosynthetix. The five year grant is to study the development of a combination therapy that […]
NIH Funding to Boston University, UNCG, Mycosynthetix, and others for nanoparticle-based innovative therapy to treat drug resistant cancer
Mycosynthetix in Brazil for Thinking Big About Small Beings: Recent Advances On Microbial Diversity, Ecology and Biodiscovery
Mycosynthetix presented at Thinking Big About Small Beings: Recent Advances On Microbial Diversity, Ecology and Biodiscovery in São Paulo, Brazil on April 28-29. The presentation was titled Searching for Anti-Cancer and Anti-Parasite Leads from Filamentous Fungi. Abstract: Fungi have been the source of numerous successful medicines and pesticides although it isn’t obvious why fungi make […]
Mycosynthetix CEO Dr. Cedric Pearce has given presentations on natural products in Japan and Canada recently. In Japan he spoke at the Mycological Society of Japan Meeting at the Tokyo University of Agriculture and the Microbial Workshop at Tamagawa University. In Canada he presented at the Weed Science Society of America/Canadian Weed Science Society Joint […]
Mycosynthetix CEO Dr. Cedric Pearce was featured on the May 8, 2013 edition of Radio In Vivo, a weekly broadcast that features in-depth interviews with the researchers who make the Research Triangle of North Carolina one of the world’s leading hubs of scientific research and development. In the interview, Dr. Pearce discusses the origins of Mycosythetix, […]
Mycosynthetix is pleased to present our new website. If you encounter any problems using our website, please don’t hesitate to let us know.
We are pleased to celebrate 10 years of Mycosynthetix. We look forward to further developing the potential for world-changing natural products from the fungal kingdom in the coming decade.
Mycosynthetix, Inc has been awarded two Therapeutic Discovery Project Grants by the IRS. The grants are for projects that “showed significant potential to produce new and cost-saving therapies, support jobs and increase U.S. competitiveness.”
Mycosynthetix CEO, Dr. Cedric Pearce, and colleagues presented at the 51st Annual Meeting of the American Society of Pharmacognosy in Tampa, Florida this July. Their presentation focused on the antimalarial compounds which have been discovered within microorganisms, such as the fungi in the Mycosynthetix library.
“Fungi are the most prolific degraders of plant biomass in nature and are expected to hold the keys to unlocking the potential of cellulose as a renewable feedstock.” Shortly after the posting of this release, Verenium’s biofuels division was acquired by British Petroleum. Mycosynthetix’ contract has been transferred to BP in the exchange.
Mycosynthetix, Inc. was recently awarded a Phase I Small Business Innovation Research grant from the National Institutes of Allergy and Infectious Diseases for the project New Tuberculosis Antibiotics from Filamentous Fungi.